ALK and non-small cell lung carcinoma: Clinical trials including ALK- and ROS1-positive patients demonstrated the efficacy of lorlatinib in subsequent lines of therapy with high intracranial response rates (RRs).15,16 We here report on the results of the German early access program (EAP) of lorlatinib, providing data on mostly heavily pretreated patients with ALK- and ROS1-alterated NSCLC from the daily routine.